Cutaneous lymphoproliferative disorders: Back to the future

Abstract

AbstractIn the 1980s, immunohistochemistry and clonality analyses became instrumental in the recognition and definition of new types of cutaneous T‐cell lymphoma (CTCL) and cutaneous B‐cell lymphoma (CBCL) and the development of new classifications. By accepting loss of pan‐T‐cell antigens and clonal T‐cell receptor gene rearrangements as important criteria to differentiate between benign and malignant T‐cell proliferations, and monotypic immunoglobulin light‐chain expression and clonal immunoglobulin gene rearrangements as crucial criteria to distinguish between benign and malignant B‐cell proliferations, many cases, until then diagnosed as cutaneous lymphoid hyperplasia or pseudolymphoma, were reclassified as primary cutaneous CD4+ small/medium T‐cell lymphoma (PCSM‐TCL) or primary cutaneous marginal zone lymphoma (PCMZL), respectively. However, in recent years there is growing awareness that neither these immunohistochemical criteria nor demonstration of T‐cell or B‐cell clonality is specific for malignant lymphomas. In addition, many studies have reported that these low‐grade malignant CTCL and CBCL have an indolent clinical behavior and an excellent prognosis with disease‐specific survival rates of or close to 100%. As a result, recent classifications have downgraded several low‐grade malignant cutaneous lymphomas to lymphoproliferative disorder (LPD). Both the 5th edition of the WHO classification (2022) and the 2022 International Consensus Classification (ICC) of mature lymphoid neoplasms reclassified PCSM‐TCL as primary cutaneous CD4+ small/medium T‐cell LPD and primary cutaneous acral CD8+ T‐cell lymphoma as primary cutaneous acral CD8+ T cell LPD. While the 2022 ICC introduced the term “primary cutaneous marginal zone LPD,” in the 5th edition of the WHO classification PCMZL is maintained. In this review we describe the background and rationale of the continually changing terminology of these conditions and discuss the clinical consequences of downgrading malignant lymphomas to LPDs.